Product
JNJ-88998377
1 clinical trial
4 indications
Indication
lymphomaIndication
Non-HodgkinIndication
Refractory B-cell Non-Hodgkin LymphomaIndication
Relapsed B-cell NHLClinical trial
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Status: Recruiting, Estimated PCD: 2027-10-29